Stock CYCC CYCLACEL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
1.57 USD -10.80% Intraday chart for Cyclacel Pharmaceuticals, Inc. -25.59% -41.20%
Apr. 01 Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer CI
Mar. 19 Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cyclacel Pharmaceuticals : April 2024 Corporate Presentation
PU
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
CI
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000
MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be presented at the American Association for Cancer Research Annual Meeting 2024
AQ
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
AQ
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO and Investor Conference
AQ
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
AQ
Cyclacel Pharmaceuticals, Inc. Announces Board Changes
CI
Cyclacel Pharmaceuticals, Inc. Announces Executive Changes
CI
Top Premarket Gainers
MT
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
AQ
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $0.026374 million in funding
CI
North American Morning Briefing : S&P 500 Futures -2-
DJ
Brookline Capital Downgrades Cyclacel Pharmaceuticals to Hold From Buy
MT
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
CI
Reverse Split: 1 of 15
FA
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYCC Stock
  4. News Cyclacel Pharmaceuticals, Inc.